NASDAQ:GILD - Gilead Sciences Stock Price, Price Target & More

$73.25 +0.53 (+0.73 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$73.25
Today's Range$72.47 - $73.56
52-Week Range$63.76 - $89.54
Volume6.00 million shs
Average Volume7.95 million shs
Market Capitalization$96.50 billion
P/E Ratio8.56
Dividend Yield3.08%

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic


Debt-to-Equity Ratio1.53%
Current Ratio2.74%
Quick Ratio2.67%


Trailing P/E Ratio8.56
Forward P/E Ratio11.59
P/E Growth-1.67

Sales & Book Value

Annual Sales$26.11 billion
Price / Sales3.66
Cash Flow$9.5254 per share
Price / Cash7.69
Book Value$15.69 per share
Price / Book4.67


EPS (Most Recent Fiscal Year)$8.56
Net Income$4.63 billion
Net Margins17.73%
Return on Equity50.29%
Return on Assets17.85%


Outstanding Shares1,303,850,000

How to Become a New Pot Stock Millionaire

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, February 6th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share on Thursday, March 29th. This represents a $2.28 annualized dividend and a dividend yield of 3.11%. The ex-dividend date is Thursday, March 15th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.52. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences (NASDAQ:GILD) announced its quarterly earnings results on Tuesday, February, 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.67 by $0.11. The biopharmaceutical company had revenue of $5.95 billion for the quarter, compared to analysts' expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company's revenue for the quarter was down 18.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.70 earnings per share. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

25 equities research analysts have issued 1 year price targets for Gilead Sciences' shares. Their predictions range from $73.77 to $105.00. On average, they anticipate Gilead Sciences' share price to reach $88.7033 in the next year. View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:
  • 1. According to Zacks Investment Research, "Gilead’s HIV franchise continues to gain traction, courtesy of the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 62% of total HIV prescription volume following the launch of Genvoya, Odefsey and Descovy in 2016. The approval of Gilead’s latest triple HIV therapy, Biktarvy, is likely to provide an impetus to the stock as Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy post Kite acquisition. Shares of the company have outperformed the industry in the last twelve months. However, the HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. Both pricing and market share are expected to stabilize by mid-2018 while patient starts are expected to decline further." (4/19/2018)
  • 2. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
  • 3. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)
  • 4. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a decline in short interest in the month of March. As of March 29th, there was short interest totalling 18,219,703 shares, a decline of 9.1% from the March 15th total of 20,048,876 shares. Based on an average trading volume of 7,317,354 shares, the short-interest ratio is currently 2.5 days. Approximately 1.4% of the shares of the stock are sold short.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:
  • Dr. John F. Milligan Ph.D., Pres, CEO & Director (Age 57)
  • Ms. Robin L. Washington, Chief Financial Officer and Exec. VP (Age 55)
  • Dr. Norbert W. Bischofberger, Exec. VP of R&D and Chief Scientific Officer (Age 62)
  • Mr. Kevin B. Young, Chief Operating Officer (Age 60)
  • Mr. Gregg H. Alton, Exec. VP of Corp. & Medical Affairs and Interim Head of International Commercial Operations (Age 52)

Has Gilead Sciences been receiving favorable news coverage?

News headlines about GILD stock have trended positive this week, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gilead Sciences earned a news impact score of 0.29 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.18 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $73.25.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $96.50 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (GILD)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  1,691 (Vote Outperform)
Underperform Votes:  643 (Vote Underperform)
Total Votes:  2,334
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Gilead Sciences (NASDAQ:GILD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
25 Wall Street analysts have issued ratings and price targets for Gilead Sciences in the last 12 months. Their average twelve-month price target is $88.7033, suggesting that the stock has a possible upside of 21.10%. The high price target for GILD is $105.00 and the low price target for GILD is $73.77. There are currently 9 hold ratings and 16 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.652.572.61
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $88.7033$88.7033$85.4071$85.4783
Price Target Upside: 21.10% upside12.07% upside8.08% upside9.76% upside

Gilead Sciences (NASDAQ:GILD) Consensus Price Target History

Price Target History for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Credit Suisse GroupSet Price TargetHold$80.00LowView Rating Details
3/6/2018BarclaysReiterated RatingOverweight -> Overweight$90.00 -> $95.00LowView Rating Details
2/23/2018Royal Bank of CanadaReiterated RatingBuy$94.00LowView Rating Details
2/22/2018Leerink SwannReiterated RatingMkt Perform -> Market Perform$83.00 -> $80.00LowView Rating Details
2/12/2018MizuhoReiterated RatingBuy -> Buy$83.00 -> $95.00LowView Rating Details
2/8/2018BMO Capital MarketsBoost Price TargetOutperform -> Market Perform$86.00 -> $88.00HighView Rating Details
2/8/2018CitigroupReiterated RatingBuy -> Buy$103.00 -> $105.00HighView Rating Details
2/7/2018Morgan StanleyLower Price TargetEqual Weight -> Equal Weight$87.00 -> $84.00MediumView Rating Details
2/7/2018Bank of AmericaBoost Price TargetNeutral -> Neutral$82.00 -> $87.00MediumView Rating Details
2/6/2018Maxim GroupSet Price TargetBuy$94.00HighView Rating Details
1/26/2018Jefferies GroupUpgradeHold -> Buy$81.19 -> $93.00HighView Rating Details
1/16/2018Wells FargoUpgradeMarket Perform -> Outperform$79.02 -> $96.00LowView Rating Details
12/21/2017OppenheimerReiterated RatingHoldMediumView Rating Details
11/13/2017ArgusDowngradeBuy -> Hold$73.25 -> $73.77N/AView Rating Details
10/25/2017JPMorgan ChaseSet Price TargetBuy$85.00N/AView Rating Details
10/19/2017William BlairReiterated RatingBuyN/AView Rating Details
10/19/2017Berenberg BankSet Price TargetBuy$96.00N/AView Rating Details
10/5/2017CIBCInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
8/31/2017CowenReiterated RatingOutperform$90.00MediumView Rating Details
8/31/2017Deutsche BankReiterated RatingBuy$81.00MediumView Rating Details
8/29/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
8/28/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
7/26/2017Redburn PartnersInitiated CoverageBuyMediumView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
4/21/2017Piper JaffrayReiterated RatingBuyLowView Rating Details
3/13/2017Goldman SachsReiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
3/9/2017UBSReiterated RatingNeutral -> Neutral$118.00 -> $72.00N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
(Data available from 4/25/2016 forward)


Gilead Sciences (NASDAQ:GILD) Earnings History and Estimates Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Earnings Estimates

2018 EPS Consensus Estimate: $6.29
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$1.55$1.79$1.67
Q2 20183$1.46$1.69$1.60
Q3 20183$1.38$1.66$1.54
Q4 20183$1.31$1.66$1.48

Gilead Sciences (NASDAQ GILD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018$1.64N/AView Earnings Details
2/6/2018Q4 2017$1.67$1.78$5.7118 billion$5.9490 billionViewListenView Earnings Details
10/26/2017Q3 2017$2.13$2.27$6.3970 billion$6.5120 billionViewN/AView Earnings Details
7/26/2017Q2 2017$2.11$2.56$6.3503 billion$7.1410 billionViewN/AView Earnings Details
5/2/2017Q1 2017$2.18$2.20$6.6604 billion$6.5050 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.2240 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.3140 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$4.9990 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.7828 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.5687 billion$2.5316 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.5880 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
7/26/2011Q2 2011$0.48$0.47ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
10/19/2010Q3 2010$0.42$0.43ViewN/AView Earnings Details
7/20/2010Q2 2010$0.41$0.40ViewN/AView Earnings Details
4/20/2010Q1 2010$0.46$0.47ViewN/AView Earnings Details
1/26/2010Q4 2009$0.41$0.45ViewN/AView Earnings Details
10/20/2009Q3 2009$0.35$0.37ViewN/AView Earnings Details
7/21/2009Q2 2009$0.31$0.33ViewN/AView Earnings Details
4/21/2009Q1 2009$0.30$0.32ViewN/AView Earnings Details
1/27/2009Q4 2008$0.28$0.30ViewN/AView Earnings Details
10/16/2008Q3 2008$0.25$0.26ViewN/AView Earnings Details
7/17/2008Q2 2008$0.25$0.23ViewN/AView Earnings Details
4/16/2008Q1 2008$0.24$0.26ViewN/AView Earnings Details
1/23/2008Q4 2007$0.21$0.21ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Gilead Sciences (NASDAQ:GILD) Dividend Information

Gilead Sciences pays an annual dividend of $2.28 per share, with a dividend yield of 3.11%. GILD's most recent quarterly dividend payment was Thursday, March 29. Gilead Sciences pays out 26.64% of its earnings out as a dividend.
Most Recent Dividend:3/29/2018
Annual Dividend:$2.28
Dividend Yield:3.11%
Payout Ratio:26.64% (Trailing 12 Months of Earnings)
36.08% (Based on This Year's Estimates)
37.94% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Gilead Sciences (NASDAQ GILD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.16%
Institutional Ownership Percentage: 78.40%
Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2018John Francis CoganDirectorSell5,833$73.74$430,125.4258,452View SEC Filing  
4/13/2018John Francis CoganDirectorSell5,833$75.56$440,741.4858,452View SEC Filing  
4/6/2018John Francis CoganDirectorSell5,833$74.47$434,383.5158,452View SEC Filing  
4/2/2018John C MartinDirectorSell50,000$73.14$3,657,000.003,067,762View SEC Filing  
3/23/2018John Francis CoganDirectorSell5,833$75.02$437,591.6658,452View SEC Filing  
3/16/2018John Francis CoganDirectorSell5,833$80.09$467,164.9758,452View SEC Filing  
3/12/2018John Francis CoganDirectorSell5,833$80.93$472,064.69View SEC Filing  
3/1/2018Gregg H AltonEVPSell25,000$78.69$1,967,250.0069,426View SEC Filing  
3/1/2018John C MartinChairmanSell50,000$78.65$3,932,500.003,067,762View SEC Filing  
2/28/2018Robin L WashingtonCFOSell5,000$80.31$401,550.0023,749View SEC Filing  
2/20/2018Gregg H AltonEVPSell14,435$81.54$1,177,029.90View SEC Filing  
2/9/2018Gayle E WilsonDirectorSell60,000$77.92$4,675,200.00182,258View SEC Filing  
2/1/2018Gregg H AltonEVPSell25,000$83.51$2,087,750.0062,738View SEC Filing  
2/1/2018John C MartinChairmanSell50,000$83.56$4,178,000.003,046,766View SEC Filing  
1/16/2018James R MeyersEVPSell100,000$80.24$8,024,000.00102,715View SEC Filing  
1/11/2018Gregg H AltonEVPSell30,000$79.00$2,370,000.0057,114View SEC Filing  
1/2/2018Gregg H AltonEVPSell15,000$73.87$1,108,050.0064,613View SEC Filing  
1/2/2018John C MartinInsiderSell50,000$73.62$3,681,000.003,046,766View SEC Filing  
12/1/2017Gregg H AltonEVPSell15,000$74.64$1,119,600.0070,988View SEC Filing  
12/1/2017John C MartinInsiderSell73,333$74.98$5,498,508.343,070,099View SEC Filing  
11/13/2017John F MilliganInsiderSell220,000$72.88$16,033,600.00View SEC Filing  
11/1/2017Gregg H AltonEVPSell15,000$74.82$1,122,300.0077,363View SEC Filing  
11/1/2017John C MartinInsiderSell73,333$75.13$5,509,508.293,070,099View SEC Filing  
10/2/2017Gregg H AltonEVPSell25,000$82.65$2,066,250.00View SEC Filing  
10/2/2017John C MartinInsiderSell73,333$82.56$6,054,372.48View SEC Filing  
9/7/2017Robin L WashingtonCFOSell51,820$85.00$4,404,700.0043,352View SEC Filing  
9/1/2017Gregg H AltonEVPSell25,000$83.05$2,076,250.00101,488View SEC Filing  
9/1/2017John C MartinInsiderSell73,333$83.11$6,094,705.632,996,766View SEC Filing  
8/31/2017James R MeyersEVPSell60,000$83.19$4,991,400.0062,715View SEC Filing  
8/30/2017Gregg H AltonEVPSell50,000$79.00$3,950,000.00113,237View SEC Filing  
8/1/2017Gregg H AltonEVPSell15,000$75.88$1,138,200.00106,113View SEC Filing  
8/1/2017John C MartinInsiderSell73,333$75.86$5,563,041.383,199,969View SEC Filing  
7/21/2017Gregg H AltonEVPSell40,000$74.00$2,960,000.00137,488View SEC Filing  
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00102,988View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.003,199,969View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.7547,562View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.943,199,969View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00117,988View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.833,204,433View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00121,761View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.003,231,096View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00132,964View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.001,128,963View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.003,287,810View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.004,119,727View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.0064,122View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.001,170,963View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.004,119,727View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.0063,122View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.001,170,963View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.0063,122View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.004,119,727View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.001,170,963View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.0062,939View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00177,964View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.001,170,963View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.004,119,727View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.0063,122View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00147,090View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50110,523View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.003,948,066View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.0048,783View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.003,948,066View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.0048,783View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00127,936View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.001,029,108View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.0044,309View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00131,422View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.003,948,066View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00133,422View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00165,168View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.001,029,108View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00133,422View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.003,948,066View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.0048,783View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00135,422View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.001,029,108View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.003,948,066View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00101,769View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.213,948,066View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00119,302View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.0049,832View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00130,694View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.504,429,387View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.0012,778View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.0049,832View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00119,302View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.0039,542View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.8428,562View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00132,694View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.504,429,387View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.0039,542View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00119,302View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.9628,562View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.0084,484View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.504,257,235View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00216,418View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.0032,938View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.002,159,643View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00161,840View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.002,159,643View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.0046,938View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.744,057,121View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.002,159,643View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Gilead Sciences (NASDAQ GILD) News Headlines

Gilead Sciences: Tempting In 2018Gilead Sciences: Tempting In 2018 - April 25 at 3:10 PM
Interesting GILD Put And Call Options For July 20thInteresting GILD Put And Call Options For July 20th - April 25 at 3:10 PM
Gilead Sciences has a Strong Oncology Research ProgramGilead Sciences has a Strong Oncology Research Program - April 25 at 3:10 PM
U.S. court upholds dismissal of $200 million Merck verdict against GileadU.S. court upholds dismissal of $200 million Merck verdict against Gilead - April 25 at 3:10 PM
This Small Biotech Is Building on a Surprising SuccessThis Small Biotech Is Building on a Surprising Success - April 24 at 3:10 PM
Is Bellicum Pharmaceuticals, Inc. a Buy?Is Bellicum Pharmaceuticals, Inc. a Buy? - April 24 at 3:10 PM
Can Gilead Sciences Inc’s (NASDAQ:GILD) ROE Continue To Surpass The Industry Average?Can Gilead Sciences Inc’s (NASDAQ:GILD) ROE Continue To Surpass The Industry Average? - April 24 at 5:12 AM
Gilead Sciences (GILD) Director Sells $430,125.42 in StockGilead Sciences (GILD) Director Sells $430,125.42 in Stock - April 23 at 10:20 PM
Gilead: Will Medicare Boost Yescarta Sales?Gilead: Will Medicare Boost Yescarta Sales? - April 23 at 3:03 PM
Q1 Earnings Surprise Well in Cards: Healthcare ETFs to BuyQ1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy - April 23 at 3:03 PM
Gilead Sciences (GILD) Set to Announce Quarterly Earnings on MondayGilead Sciences (GILD) Set to Announce Quarterly Earnings on Monday - April 23 at 4:12 AM
Exploring the Financial Performance of Sarepta TherapeuticsExploring the Financial Performance of Sarepta Therapeutics - April 21 at 3:10 PM
Gilead Sciences (GILD) "Buy" Rating Reaffirmed at Jefferies GroupGilead Sciences' (GILD) "Buy" Rating Reaffirmed at Jefferies Group - April 19 at 10:12 PM
Gilead Sciences (GILD) Given Overweight Rating at JPMorgan ChaseGilead Sciences (GILD) Given Overweight Rating at JPMorgan Chase - April 19 at 10:12 PM
Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drugGilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug - April 19 at 3:10 PM
Gilead Sciences (GILD) Equal Weight Rating Reiterated at Morgan StanleyGilead Sciences' (GILD) Equal Weight Rating Reiterated at Morgan Stanley - April 19 at 2:58 PM
Gilead Sciences (GILD) Rating Increased to Buy at Zacks Investment ResearchGilead Sciences (GILD) Rating Increased to Buy at Zacks Investment Research - April 19 at 11:46 AM
Q1 2018 EPS Estimates for Gilead Sciences (GILD) Lifted by Leerink SwannQ1 2018 EPS Estimates for Gilead Sciences (GILD) Lifted by Leerink Swann - April 19 at 7:08 AM
Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead CompanyAstellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company - April 19 at 5:16 AM
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson TherapeuticsBiotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics - April 18 at 3:10 PM
AbbVie’s Duodopa, Creon, Synagis, Synthroid, and SevofluraneAbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane - April 18 at 3:10 PM
Why Big Biotech Stocks May Get An Earnings BoostWhy Big Biotech Stocks May Get An Earnings Boost - April 18 at 3:10 PM
Big Biotech ETF Can Bounce BackBig Biotech ETF Can Bounce Back - April 18 at 3:10 PM
Gilead Sciences (GILD) Given a $80.00 Price Target by Credit Suisse Group AnalystsGilead Sciences (GILD) Given a $80.00 Price Target by Credit Suisse Group Analysts - April 18 at 9:22 AM
FY2020 EPS Estimates for Gilead Sciences Increased by Leerink Swann (GILD)FY2020 EPS Estimates for Gilead Sciences Increased by Leerink Swann (GILD) - April 18 at 8:56 AM
Q1 2018 Earnings Forecast for Gilead Sciences (GILD) Issued By William BlairQ1 2018 Earnings Forecast for Gilead Sciences (GILD) Issued By William Blair - April 18 at 7:55 AM
Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018 - April 18 at 5:07 AM
Gilead Sciences (GILD) Downgraded to "Hold" at Zacks Investment ResearchGilead Sciences (GILD) Downgraded to "Hold" at Zacks Investment Research - April 17 at 5:27 PM
Gilead Sciences (GILD) Rating Increased to Hold at BidaskClubGilead Sciences (GILD) Rating Increased to Hold at BidaskClub - April 16 at 8:40 PM
Gilead Sciences (GILD) Director Sells $440,741.48 in StockGilead Sciences (GILD) Director Sells $440,741.48 in Stock - April 16 at 7:14 PM
Gilead (GILD) Presents Encouraging Data on NASH TherapiesGilead (GILD) Presents Encouraging Data on NASH Therapies - April 16 at 3:18 PM
How AbbVie Performed in 4Q17 and Fiscal 2017How AbbVie Performed in 4Q17 and Fiscal 2017 - April 16 at 3:18 PM
Gilead Sciences (GILD) Hold Rating Reiterated at Maxim GroupGilead Sciences' (GILD) Hold Rating Reiterated at Maxim Group - April 15 at 4:33 PM
Gilead Sciences (GILD) PT Set at $85.00 by JPMorgan ChaseGilead Sciences (GILD) PT Set at $85.00 by JPMorgan Chase - April 15 at 4:33 PM
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International ...Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International ... - April 14 at 5:02 AM
Gilead (GILD) Presents Data on Multiple Investigational Regimens for Treatment of NASH and Advanced Fibrosis at The International Liver CongressGilead (GILD) Presents Data on Multiple Investigational Regimens for Treatment of NASH and Advanced Fibrosis at The International Liver Congress - April 14 at 5:02 AM
3 Top Healthcare Stocks to Buy in April3 Top Healthcare Stocks to Buy in April - April 14 at 5:02 AM
Gilead Sciences (GILD) Upgraded at BidaskClubGilead Sciences (GILD) Upgraded at BidaskClub - April 14 at 12:49 AM
Gilead combo therapy for NASH shows encouraging action in proof-of-concept studyGilead combo therapy for NASH shows encouraging action in proof-of-concept study - April 13 at 3:12 PM
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic ...Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic ... - April 13 at 3:12 PM
Is Gilead Sciences, Inc. (GILD) a Buy?Is Gilead Sciences, Inc. (GILD) a Buy? - April 13 at 3:12 PM
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018 - April 13 at 3:12 PM
Why One Drug Flop Tanked Incyte's StockWhy One Drug Flop Tanked Incyte's Stock - April 13 at 5:03 AM
[$$] How Big Biotech Can Win Back Investors[$$] How Big Biotech Can Win Back Investors - April 13 at 5:03 AM
 Brokerages Expect Gilead Sciences (GILD) Will Post Quarterly Sales of $5.37 Billion Brokerages Expect Gilead Sciences (GILD) Will Post Quarterly Sales of $5.37 Billion - April 13 at 3:48 AM
Gilead Sciences (GILD) Sees Significant Decline in Short InterestGilead Sciences (GILD) Sees Significant Decline in Short Interest - April 13 at 3:43 AM
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?' - April 12 at 3:08 PM
Silicon Valley’s 10 highest-paid CEOs may not be who you'd expectSilicon Valley’s 10 highest-paid CEOs may not be who you'd expect - April 12 at 3:08 PM
Goldman Sachs asks in biotech research report: Is curing patients a sustainable business model?Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?' - April 12 at 5:15 AM
BidaskClub Downgrades Gilead Sciences (GILD) to HoldBidaskClub Downgrades Gilead Sciences (GILD) to Hold - April 11 at 10:10 PM

SEC Filings

Gilead Sciences (NASDAQ:GILD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Gilead Sciences (NASDAQ:GILD) Income Statement, Balance Sheet and Cash Flow Statement


Gilead Sciences (NASDAQ GILD) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.